Literature DB >> 29061371

Puerarin acts on the skeletal muscle to improve insulin sensitivity in diabetic rats involving μ-opioid receptor.

Xiufang Chen1, Lei Wang2, Shanshan Fan2, Shiyu Song2, Haiyan Min2, Yongzheng Wu2, Xuan He2, Qiao Liang2, Yong Wang3, Long Yi2, Qian Gao4.   

Abstract

Puerarin, a major active isoflavone extracted from the root of Pueraria lobate, significantly increases plasma β-endorphin and insulin levels and improves impaired insulin signaling in diabetic animals. However, the target tissues and underlying mechanisms in and through which puerarin functions to ameliorating insulin resistance remains largely unclear. In this study, we showed that puerarin enhanced μ-opioid receptor expression and phosphorylation, and increased insulin-stimulated glucose transporter 4 translocation to the plasma membrane in the skeletal muscle of diabetic rats, which were recaptured by a direct application of puerarin in the palmitate-induced insulin-resistant L6 myotubes. Naloxone, an antagonist of μ-opioid receptor, blocked these functions of puerarin. No β-endorphin was detected either in the muscle of diabetic rats or in the palmitate-induced insulin-resistant L6 cells. Furthermore, we presented the evidence to show the interaction between μ-opioid receptor and insulin receptor substrate 1 in the muscle tissues and cells. These results suggested that puerarin improved insulin sensitivity in the skeletal muscle at least in part by its local effects involving μ-opioid receptor function.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2-NBDG (PubChem CID: 6711157); Diabetes; Insulin (Bovine) (PubChem CID: 16131099); Insulin resistance; Naloxone hydrochloride dihydrate (PubChem CID: 20112022); Palmitate (PubChem CID: 985); Puerarin; Puerarin (PubChem CID: 5281807); Skeletal muscle; Streptozocin (PubChem CID: 29327); μ-opioid receptor

Mesh:

Substances:

Year:  2017        PMID: 29061371     DOI: 10.1016/j.ejphar.2017.10.033

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Chitosan@Puerarin hydrogel for accelerated wound healing in diabetic subjects by miR-29ab1 mediated inflammatory axis suppression.

Authors:  Xiaoling Zeng; Baohui Chen; Luping Wang; Yingxiao Sun; Zhao Jin; Xuanyong Liu; Liping Ouyang; Yun Liao
Journal:  Bioact Mater       Date:  2022-05-11

2.  Succinylated whey protein isolate as a sustained-release excipient of puerarin derivative oral tablets: Preparation, optimization and pharmacokinetics.

Authors:  Rui Zhang; Yu Zhang; Yue Wu; Jun Liu; Tiantian Ye; Shujun Wang
Journal:  Asian J Pharm Sci       Date:  2018-05-10       Impact factor: 6.598

3.  The immune-opioid axis in prediabetes: predicting prediabetes with insulin resistance by plasma interleukin-10 and endomorphin-2 to kappa-opioid receptors ratio.

Authors:  Shatha Rouf Moustafa
Journal:  Diabetol Metab Syndr       Date:  2021-06-07       Impact factor: 3.320

Review 4.  Molecular Mechanism of Puerarin Against Diabetes and its Complications.

Authors:  Yi-Ling Bai; Ling-Ling Han; Jun-Hui Qian; Hao-Zhong Wang
Journal:  Front Pharmacol       Date:  2022-01-04       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.